KMT2A and leukemia: We will discuss therapies targeting the singular H3K9 methyltransferase DOT1L and the H3K4 methyltransferase MLL1 next, as these have been or are now in clinical stages of development for the treatment of various leukemias (Table 1 and Table 2).